Simultaneous targeting of 5-LOX-COX and ODC block NNK-induced lung adenoma progression to adenocarcinoma in A/J mice.
Lung cancer is the leading cause of cancer deaths worldwide. Targeting complementary pathways will achieve better treatment efficacy than a single agent high-dose strategy that could increase risk of side effects and tumor resistance. To target COX-2, 5-LOX, and ODC simultaneously, we tested the effects of a dual 5-LOX-COX inhibitor, licofelone, and an ODC inhibitor, DFMO, alone and in combination, on NNK-induced lung tumors in female A/J mice. Seven-week-old mice were treated with NNK (10 μmol/mouse, single dose, i.p.) and randomized to different treatment groups. Three weeks after injection, mice were fed control or experimental diets (DFMO 1500/3000 ppm, licofelone 200/400 ppm, or a low-dose combination of 1500 ppm DFMO and 200 ppm licofelone) for 17 or 34 weeks. Both agents significantly inhibited tumor formation in a dose-dependent manner. As anticipated more adenomas and adenocarcinomas were observed at 17 and 34 weeks, respectively. Importantly, low dose combination of DFMO and licofelone showed more pronounced effects at 17 or 34 weeks in inhibiting the total tumor formation (~60%, p < 0.0001) and adenocarcinoma (~65%, p < 0.0001) compared to individual high dose of DFMO (~44% and 46%, p < 0.0001) and licofelone (~48% and 55%, p < 0.0001). DFMO and combination-treated mice lung tumors exhibited modulated ODC pathway components (Oat, Oaz, SRM, SMS, and SAT, p < 0.05) along with decreased proliferation (PCNA, Cyclin D1 and Cyclin A) and increased expression of p53, p21 and p27 compared to mice fed control diet. Both DFMO and licofelone significantly inhibited tumor inflammatory markers. Our findings suggest that a low-dose combined treatment targeting inflammation and polyamine synthesis may provide effective chemoprevention.
Center for Cancer Prevention and Drug Development, Hematology-Oncology Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK 73104, USA.
Gaurav
G
Kumar
Center for Cancer Prevention and Drug Development, Hematology-Oncology Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK 73104, USA.
Jagan Mohan R
JM
Patlolla
Center for Cancer Prevention and Drug Development, Hematology-Oncology Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK 73104, USA.
Venkateshwar
V
Madka
Center for Cancer Prevention and Drug Development, Hematology-Oncology Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK 73104, USA.
Altaf
A
Mohammed
Center for Cancer Prevention and Drug Development, Hematology-Oncology Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK 73104, USA.
Qian
Q
Li
Center for Cancer Prevention and Drug Development, Hematology-Oncology Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK 73104, USA.
Yuting
Y
Zhang
Center for Cancer Prevention and Drug Development, Hematology-Oncology Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK 73104, USA.
Laura
L
Biddick
Center for Cancer Prevention and Drug Development, Hematology-Oncology Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK 73104, USA.
Anil
A
Singh
Division of Cancer Prevention, Chemoprevention Agent Development Research Group, National Cancer Institute Bethesda, MD, USA.
Allison
A
Gillaspy
Center for Cancer Prevention and Drug Development, Hematology-Oncology Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK 73104, USA.
Stanley
S
Lightfoot
Division of Cancer Prevention, Chemoprevention Agent Development Research Group, National Cancer Institute Bethesda, MD, USA.
Vernon E
VE
Steele
Division of Cancer Prevention, Chemoprevention Agent Development Research Group, National Cancer Institute Bethesda, MD, USA.
Levy
L
Kopelovich
Center for Cancer Prevention and Drug Development, Hematology-Oncology Section, Department of Medicine, Stephenson Cancer Center, University of Oklahoma Health Sciences Center Oklahoma City, OK 73104, USA.
Chinthalapally V
CV
Rao
Cox-2; DFMO; Lung cancer; chemoprevention; licofelone; ornithine decarboxylase